Lilly, Novo, BMS return to boost BGV's largest European biotech fund yet

Eli Lilly, Novo Holdings and Bristol Myers Squibb, which have all invested in the fund in previous years, have come back for the latest fundraise. Netherlands-based BGV is focused on early-stage VC and said the latest haul will “build on the successful investment strategy of previous BGV funds” with the money to be shared among about 12 companies.